Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.4 USD | -3.73% | -5.76% | -30.89% |
Financials (USD)
Sales 2024 * | 822M | Sales 2025 * | 1.22B | Capitalization | 5.22B |
---|---|---|---|---|---|
Net income 2024 * | -108M | Net income 2025 * | 171M | EV / Sales 2024 * | 5.97 x |
Net cash position 2024 * | 317M | Net cash position 2025 * | 815M | EV / Sales 2025 * | 3.62 x |
P/E ratio 2024 * |
-48.5
x | P/E ratio 2025 * |
34.6
x | Employees | 704 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.7% |
Latest transcript on Apellis Pharmaceuticals, Inc.
1 day | -1.46% | ||
1 week | -2.08% | ||
Current month | -2.73% | ||
1 month | -16.53% | ||
3 months | -36.21% | ||
6 months | -10.71% | ||
Current year | -28.19% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Andrew Dunlop
BRD | Director/Board Member | 52 | 10-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.61% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - | |
0.19% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 41.37 | -3.81% | 643 916 |
24-05-13 | 43.01 | +2.43% | 1,153,471 |
24-05-10 | 41.99 | -1.25% | 979,770 |
24-05-09 | 42.52 | +0.52% | 1,060,526 |
24-05-08 | 42.3 | -3.64% | 2,160,470 |
Delayed Quote Nasdaq, May 14, 2024 at 10:26 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.19% | 5.22B | |
-2.47% | 89.37B | |
+2.76% | 40.65B | |
-13.80% | 32.81B | |
+51.20% | 25B | |
-16.75% | 15.29B | |
-42.60% | 11.61B | |
-12.82% | 11.49B | |
+5.62% | 8.98B | |
-7.72% | 8.23B |
- Stock Market
- Equities
- APLS Stock